학술논문

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
Document Type
article
Author
van der Lee, Sven JConway, Olivia JJansen, IrisCarrasquillo, Minerva MKleineidam, Lucavan den Akker, ErikHernández, Isabelvan Eijk, Kristel RStringa, NajadaChen, Jason AZettergren, AnnaAndlauer, Till FMDiez-Fairen, MonicaSimon-Sanchez, JavierLleó, AlbertoZetterberg, HenrikNygaard, MarianneBlauwendraat, CornelisSavage, Jeanne EMengel-From, JonasMoreno-Grau, SoniaWagner, MichaelFortea, JuanKeogh, Michael JBlennow, KajSkoog, IngmarFriese, Manuel APletnikova, OlgaZulaica, MirenLage, Carmende Rojas, ItziarRiedel-Heller, SteffiIllán-Gala, IgnacioWei, WeiJeune, BernardOrellana, AdelinaThen Bergh, FlorianWang, XueHulsman, MarcBeker, NinaTesi, NiccoloMorris, Christopher MIndakoetxea, BegoñaCollij, Lyduine EScherer, MartinMorenas-Rodríguez, EstrellaIronside, James Wvan Berckel, Bart NMAlcolea, DanielWiendl, HeinzStrickland, Samantha LPastor, PauRodríguez Rodríguez, EloyDESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank)EADB (Alzheimer Disease European DNA biobank)IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium)IPDGC (The International Parkinson Disease Genomics Consortium)RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia)Netherlands Brain Bank (NBB)Boeve, Bradley FPetersen, Ronald CFerman, Tanis Jvan Gerpen, Jay AReinders, Marcel JTUitti, Ryan JTárraga, LluísMaier, WolfgangDols-Icardo, OriolKawalia, AmitDalmasso, Maria CarolinaBoada, MercèZettl, Uwe Kvan Schoor, Natasja MBeekman, MarianAllen, MarietMasliah, Eliezerde Munain, Adolfo LópezPantelyat, AlexanderWszolek, Zbigniew KRoss, Owen ADickson, Dennis WGraff-Radford, Neill RKnopman, DavidRademakers, RosaLemstra, Afina WPijnenburg, Yolande ALScheltens, PhilipGasser, ThomasChinnery, Patrick FHemmer, BernhardHuisman, Martijn ATroncoso, JuanMoreno, FerminNohr, Ellen ASørensen, Thorkild IAHeutink, PeterSánchez-Juan, PascualPosthuma, DanielleGIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study GroupClarimón, Jordi
Source
Acta neuropathologica. 138(2)
Subject
DESGESCO (Dementia Genetics Spanish Consortium)
EADB
EADB
IFGC (International FTD-Genomics Consortium)
IPDGC
IPDGC
RiMod-FTD
Netherlands Brain Bank
GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group
Alzheimer’s disease
Amyotrophic lateral sclerosis
Dementia with Lewy bodies
Frontotemporal dementia
Longevity
Multiple sclerosis
Neurodegenerative disease
PLCG2
Parkinson’s disease
Phospholipase C Gamma 2
Progressive supranuclear palsy
Alzheimer's disease
Parkinson's disease
Alzheimer's Disease
frontotemporal dementia
dementia with Lewy-bodies
progressive suprauclear palsy
Parkinson's Disease
amyotrophic lateral sclerosis
multiple sclerosis
neurodegenerative disease
longevity
Clinical Sciences
Neurosciences
Neurology & Neurosurgery
Language
Abstract
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway as drug-target.